AFP and hepatocellular carcinoma: The inhibition of TNFR1 expression in HCC by using CAY10500 produced therapeutic effects as indicated by increasing the survival rate, reducing serum AFP level, decreasing liver nodules, and improving hepatocytes’ structure.